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AAT alpha-1 antitrypsin 
AATD alpha-1 antitrypsin deficiency 
ADMAPP alpha-1 antitrypsin deficiency management and prevention program 
BMI body mass index 
BRFG Big Fat Reference Guide 
CCI Charlson Comorbidity Index 
CI Confidence interval 
COPD chronic obstructive pulmonary disease 
OR odds ratio 
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Abstract 
Background: Alpha-1 antitrypsin deficiency is a heritable genetic condition that is largely 
underdiagnosed and has been estimated to affect 1 out of every 5,000-7,000 people in North 
America. The condition is characterized by a decrease in the production or activity of the alpha-1 
antitrypsin protein, increasing risk for chronic lung or liver inflammation, that may lead to 
disease. Currently, there is no cure for the condition and augmentation therapy, which replaces 
the lost protein, has shown mixed results, meaning preventive measures taken by the patient are a 
large component of the prescribed treatment. Thus, patients with the condition are strongly 
encouraged to quit smoking, reduce drinking, avoid occupations or areas that have high levels of 
particulate matter or toxic air pollutants as well as maintain active vaccinations against lung and 
liver infections like pneumonia, hepatitis A and B, and the flu to prevent complications from the 
condition. 
 
Objectives: This study aims to 1) Access the associations between adherence to the AlphaNet 
disease management and prevention program and the prophylactic measures that are encouraged 
by the program and; 2) determine if any of these associations are a result of demographic and 
health differences between individuals who are adherent ADMAPP and those who are not. 
 
Methods: This is a cross-sectional study of 3,526 individuals with alpha-1 antitrypsin deficiency 
who answered a questionnaire administered by AlphaNet from May 29th 2008 to February 14th 
2015 as part of the Alpha-1 Antitrypsin Management and Prevention Program. This study 
focused on questions related to adherence to the program and prophylactic measures taken by the 
individual that are encouraged by the literature given out by the program. Only individuals who 
 3 
 
answered questions about their adherence to the program were included in this current study. 
Demographic differences between the two stratified populations and an index for comorbidities 
were used for logistic regression analysis.  
 
Results: After adjustment for sex, age, income, and comorbidies, compared with individuals who 
self-reported as being non-adherent to the disease management and prevention program, adherent 
individuals were more likely to be comfortable with their knowledge of the disease (ORadj=4.95, 
95% CI: 3.24-7.57), have read any part of the literature provided by the program (ORadj=6.44, 
95% CI: 5.45-7.62), and use augmentation therapy (ORadj=2.08, 95% CI: 1.53-2.82). These 
individuals were also more likely to be vaccinated for the flu (ORadj=1.34, 95% CI: 1.08-1.68), 
Hepatitis A (ORadj=1.41, 95% CI: 1.20-1.66), and Hepatitis B (ORadj=1.62, 95% CI: 1.37-1.91), 
as well as exercise (ORadj=2.07, 95% CI: 1.74-2.47), while being less likely to be active smokers 
(ORadj=0.47, CI: 0.31-0.70). 
 
Conclusions: This study suggests that AlphaNet program may be a useful tool for informing and 
improving preventive measures taken by individuals with alpha-1 antitrypsin deficiency. 
Individuals who self-reported their percent adherence to the program as being nonzero were 
more likely to be informed about their condition and taking preventive measures, such as 
smoking cessation, getting vaccinated for conditions that could magnify the effects of AATD, 
and increases in self-reported exercise. Future studies are needed to show causality and 
improvement in participant outcomes such as mortality and quality of life. 
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Introduction 
Alpha-1 antitrypsin deficiency (ATTD) was first described in 1963 by Carl-Bertil Laurell and 
Sten Eriksson who observed low levels of the alpha-1 antitrypsin (ATT) protein associated with 
the symptoms of emphysema [1]. This discovery, coupled with the association of ATTD with 
liver cirrhosis has led to a recognition as ATTD as being a predisposing factor for the 
development of liver disease and emphysema. While the condition has been identified for over 
50 years, our understanding of the disease as well as the information concerning its prevalence is 
limited.  
 
ATTD is a heritable condition that, as its name suggests, is a result of an individual having lower 
levels of the alpha-1 antitrypsin (ATT) protein. Lower levels of this protein have been linked to 
numerous diseases; the majority of which are related to impaired lung function and liver disease 
[2]. Currently there are no cures for ATTD, but several treatment options are available, most of 
which are the same as the ones used to treat chronic obstructive pulmonary disease (COPD) [3]. 
Augmentation therapy, where intravenous AAT is administered to patients, usually on a weekly 
basis, as well as gene therapy have also been explored as possible treatment options [3, 4], but 
the efficacy of these treatments is debatable; there is a lack of well-designed randomized clinical 
trials, among other things [5-7]. 
 
To help patients, families of patients, and healthcare providers navigate the wealth of 
information on AATD, individuals from AlphaNet, a not-for-profit organization founded in 
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1995, have developed the Alpha-1 Disease Management and Prevention Program (ADMAPP). 
The program provides support as well as education on the disease [8]. A large part of the 
education component is devoted to prophylactic measures that individuals with ATTD can take 
to help decrease the risk of further disease complications.  
 
Since there is no active cure for ATTD, preventive measures are emphasized, such as smoking 
cessation and vaccination for certain diseases, all of which are part of the ADMAPP program. 
Therefore, the purpose of this analysis was to: 1) access the associations between adherence to 
the AlphaNet disease management and prevention program and the prophylactic measures that 
are encouraged by the program and; 2) determine if any of these associations are a result of 
demographic and health differences between individuals who are ADMAPP adherent and those 
who are not. 
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Literature Review 
The following review of literature is a summary of current scientific knowledge and 
understanding of ATTD. It is a collection of knowledge from the molecular mechanics and 
genetics perspective, as well as a larger, epidemiological view of the topic. The works cited are a 
collection of peer-reviewed articles found on scientific literature search engines such as PubMed. 
The purpose of this review is to summarize the information available on ATTD that is applicable 
to this study and is not an exhaustive review of all the literature available.  
 
Genetics and mechanism of action 
AATD is an inherited autosomal codominant genetic condition following the Mendelian pattern 
of inheritance [9]. The condition is a result of a single nucleotide polymorphism (SNP) in the 
gene that codes for the ATT protein. These SNPs have the potential to change the amino acid 
composition of the protein and therefore the charge of the protein. The changes in charge alter 
the speed at which the proteins migrate on gel electrophoresis, which is used to characterize the 
specific phenotype of an individuals with ATTD [9]. The phenotypes are labeled alphabetically 
with the A allele having the highest rate of migration, while the more commonly observed Z 
allele having the slowest, and the M allele having the normal speed.[9, 10]. For clarity, the 
remainder of this paper will refer to the specific alleles using the common nomenclature, which 
is PI* (standing for protease inhibitor) followed by the allele (i.e. PI*ZZ for the homozygous Z 
allele phenotype).  
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The specific phenotype that a patient with ATTD has is clinically significant, as each is 
correlated with the degree of severity of the condition [10]. For instance, the PI*SZ and PI*ZZ 
mutations reduce ATT levels by 25% and 15% of normal, respectively [11]. This is in contrast to 
the more rare PI*NullNull variant, which results in the total absence of ATT due to 
transcriptional or translational errors that create a protein that is ultimately degraded [9, 11].  
 
Normally, the ATT protein functions as a serine protease inhibitor, with the most notable 
substrate being neutrophil elastase. Briefly, when immune cells known as neutrophils are 
recruited to sites of inflammation they release elastase, an enzyme with broad substrate reaction 
activity capable of attacking a number of host proteins as well as numerous xenobiotics like 
bacteria or chemicals found in smoke. The release of elastase in response to inflammation is a 
protective mechanism by the body, as the enzyme has numerous beneficial actions such as 
impairing phagocytosis of bacterial pathogens [9]. ATT helps balance the protective effects of 
the elastase while limiting the damage to the host.  
 
In individuals with ATTD, levels of ATT are decreased resulting in increased host damage. 
Importantly, the phenotype of an individual has been found to be the best determinant of ATT 
level variation [12]. In addition to decreased levels of ATT, the ATT present in ATTD 
individuals may be dysfunctional and less capable of antiprotease activity [10]. 
 
Prevalence 
The presence of ATTD varies widely among different populations [13], with the largest presence 
being detected in groups with European ancestry, particularly in the Scandinavia regions of 
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Europe [3, 14]. In addition to variable prevalence of the condition, the distribution of specific 
alleles also varies within populations [13]. This becomes especially important in North America 
where the mixed descendent population creates even more variability [15]. Prevalence 
approximations of ATTD in North American, especially the United States, are hindered by this 
fact, but it has been estimated to be as high as 1 out of every 5,000-7,000 individuals in North 
America for the non-PI*MM (normal) phenotypes [16].  
 
The figures for ATTD prevalence are further complicated by the lack of testing for the condition. 
Recent findings showing an increased prevalence in a wide array of countries indicate the 
impression of ATTD being a relatively rare disease may be a function of lack of testing. In 
addition, it has been estimated that 10-35% of individuals with certain alleles may not ever 
present with clinical symptoms, further decreasing chances of the condition being detected 
[3].These observations suggest that the condition is not rare, but rather rarely diagnosed [17].  
 
Disease Risk 
The majority of diseases associated with AATD are a result of pulmonary impairment (e.g., 
COPD, bronchiectasis), with a smaller proportion of patients having hepatic (e.g., cirrhosis, 
hepatoma) and vasculitis manifestations of the condition [2, 3, 18, 19]. Several other disease, 
such as coeliac disease and certain cancers, have been suggested as well, but the associations 
remains unclear [18]. While the specific mechanisms of the disease progression out of the scope 
of this study, it is important to note the systems affected by AATD.  
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Lung disease in patients with AATD usually manifests as emphysema or COPD and generally 
begins in early adulthood. The development of these diseases are often exacerbated by the 
presence of compounding factors such as smoking or infection [20]. Lung injury is a result of 
decreased levels of ATT in the lungs, which leads to unchallenged proteolytic damage to the 
lung tissue [3, 19]. Risk of lung disease is strongly correlated with the variant of ATTD, with 
PI*SZ, PI*ZZ, and PI*NullNull being the most significantly at risk [18]. 
 
While ATTD manifests as liver disease less frequently than lung disease, it can lead to serious 
liver dysfunction in some patients. Liver complications begin as hepatitis (inflammation of the 
liver) which can lead to liver cirrhosis. Unlike lung disease, the mechanism resulting in liver 
disease as a result of ATTD is not related to the loss of inhibitory functionality, but instead is a 
result of protein accumulation in the hepatocytes [18, 19]. In individuals with the PI*ZZ, and less 
frequently, the PI*SZ variant of ATTD, the amino acid substitution in the ATT protein causes 
the proteins to spontaneously polymerize, or bind together [19]. The polymerization of the 
protein prevents its secretion, leading to cellular inflammation and a further decrease in 
circulating ATT levels [18]. 
 
It is not surprising that all of the prophylactic measures suggested to ATTD patients focus on 
lung and liver injury prevention. ATTD patients are strongly encouraged to quit smoking, reduce 
drinking, avoid occupations or areas that have high levels of particulate matter or toxic air 
pollutants as well as maintain active vaccinations against lung and liver infections like 
pneumonia, hepatitis A and B, and the flu [20, 21]. With an impaired ability to respond to 
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xenobiotic insults, it is important that ATTD patients prevent unnecessary stress on the lungs or 
liver.  
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Methodology 
Study population 
This study uses data gathered from an introductory questionnaire that individuals with ATTD in 
the AlphaNet system completed that has been previously described elsewhere [22]. The data set 
is a collection of qualitative, self-reported, questionnaire responses containing information from 
4,747 unique individuals, with missing entry frequency varying between a few hundred to a few 
thousand. The answer date of the questionnaire ranges from May 2008 to February 2015 and 
contains up to 178 responses per individual. This data set includes basic demographic 
information (e.g. sex, race, marital status, income level), medical history (e.g. specific ATTD 
genetic variant, current medical conditions) and lifestyle choices (e.g. smoking, drinking, and 
exercise habits). 
 
The study population was determined by the response to two questions in the questionnaire 
regarding adherence to the ADMAPP. Participants were ask if they currently followed the 
guidelines of ADMAPP as well as their estimated percentage of compliance. Any participants 
who responded yes or had a percent compliance as being nonzero was considered adherent, 
while participants who responded no or had a percent compliance of zero was considered non-
adherent. After this classification process, 1,221 of the participants had missing adherence 
information and were therefore excluded from the study, leaving a final study population of 
3,526, which was further stratified into two groups based on their self-reported compliance with 
the program (Figure 1). 
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Figure 1. Flowchart of the study population.  
 
Study Design 
This is a cross sectional study aimed at identifying, assessing, and analyzing any associations 
found related to individuals with ATTD being compliant with the ADMAPP. The outcome of 
interest was on the differences in the preventive lifestyle choices between the two groups (i.e. 
smoking, drinking, vaccinations), health status (i.e. BMI, perceived health), and knowledge of 
the disease.   
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Variables 
All of the variables used in this study were generated from self-reported data. Using this self-
reported information, the following variables were used in the analysis: sex, age, race, variant of 
AATD, the reason they were originally tested and diagnosed for AATD, comfort level with 
disease knowledge, use of augmentation therapy, smoking status, drinking habits, vaccinations, 
BMI, perceived weight, fitness level, and health, exercise habits, heath care visits, and 
emergency service visits.  
 
The outcomes variables were grouped into three categorized (Disease knowledge and treatment, 
exacerbating and prophylactic factors, health and health perception) based on similarities in 
measured outcome. Disease knowledge and treatment included self-reported comfort with 
current disease knowledge, as well as whether they had read any part of the BFRG and if the 
participant was currently using any kind of augmentation therapy. Exacerbating and prophylactic 
factors included current smoking status, drinking habits, as well as whether the participant had 
received certain vaccinations. Health and health perception included exercise habits, body mass 
index (BMI), health provider visits, emergency service utilization, and perceptions on various 
aspects the participant health. 
 
The body mass index was calculated by dividing the weight by the square of the height and 
multiplying by a conversion factor of 703, per CDC guidelines [23]. The age of the participant at 
the time of survey completion was calculated by taking the difference between the date of birth 
and date the questionnaire was answered. Originally the exercise habits of individuals were 
broken up based on the location and regularity of the exercise. These variables were combined so 
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indication of exercise at any location, regardless of regularity, was categorized as an affirmative 
answer.  
 
Missing and Nonsensical Data 
This data set was not complete for all respondents. In order to remain transparent about this 
limitation, descriptive variables were reported for the individuals who were missing information 
for ADMAPP adherence. Currently, there is no consensus on how to statistically test for whether 
or not missing data is missing at random or not, which was assumed in this study. In an attempt 
to validate this assumption, statistical analysis was performed on differences between the study 
population and the missing population using various demographic and outcome variables. 
 
To help with the issue of erroneous or nonsensical data points, several decisions regarding these 
data points were made, all of which are reported below. 
 
Any variable that contained a response recorded as being unknown, was reclassified as being 
missing unless that was an option on the questionnaire. For questions that had sub-questions 
based on the answer to the original, the original answer was considered correct. For example, if 
an individual answered no to “Have you ever smoked cigarettes?” but had responses recorded for 
“How many years did you have you smoked?” or “Are you still smoking?” the responses 
following the original question of “Have you ever smoked cigarettes?” were marked as missing. 
All instances where the inch portion of a person’s height were reported as being “12” were 
marked as missing, ultimately resulting in missing information for BMI. Finally, if self-reported 
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ADMAPP compliance was reported as 0 then those individuals were recoded as being non-
compliant, while any compliance above 0 was considered to be compliant.  
 
 
Charlson Comorbidity Index 
In order to ensure differences between the two groups was not due to individuals who had more 
serious medical conditions being unequally distributed between the groups, the Charlson 
Comorbidity Index (CCI) was used. Briefly, the CCI utilizes categories of comorbidities with 
associated weight (Table 1) based on the risk of mortality. Mortality risk increases proportionally 
with the CCI score [24]. For the CCI calculations, missing or negative answers for each 
condition were given a score of 0, which is why there are no missing observations missing this 
demographic characteristic. 
Table 1. The Charlson Comorbidity Index (CCI) Scoring System 
 
Weight/Score 
 
Condition 
1 Diabetes 
 Myocardial infarction 
 Congestive heart failure  
 Peripheral vascular disease 
 Cerebrovascular disease 
 Dementia or Alzheimer’s 
 Connective tissue disease 
 Ulcer disease 
 Mild liver disease 
2 Paralysis of arms and/or legs 
 Moderate or severe kidney disease 
 Any tumor or cancer 
 Leukemia 
 Lymphoma 
3 Moderate or severe liver disease 
6 AIDS 
 Metastatic cancer 
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ADMAPP and the Big Fat Reference Guide (BFRG) 
The Big Fat Reference Guide (BFRG) is a free resource provided by the AlphaNet. It is a 
comprehensive guide meant for patients with ATTD, their families, and medical providers and is 
one of the main components of the ADMAPP. Adherence with the ADMAPP is largely 
associated with complying with the suggestions in the BFRG. Unfortunately, the question 
pertaining to ADMAPP adherence did not specifically as what parts of the program the 
individual was compliant with, but merely an estimation of overall compliance.  
 
Statistical analysis 
Data were analyzed using SAS software, Version 8 of the SAS System for Windows. 
Frequencies and percentages were reported for categorical variables for the entire population as 
well as the subgroups within the population and were compared using chi-square tests. 
Continuous variables were reported as means and standards deviations; t-tests were used for 
comparisons. P values were reported for both continuous and categorical variables, with the 
significance threshold being a P value less than 0.05.  
 
Crude odds ratios and the respective 95% confidence intervals were calculated for the variables 
of interest using the Proc Freq function. Adjusted odds ratios were calculated using the Proc 
Logistic function, controlling for age, sex, CCI, and income. Covariates were chosen based on 
differences in population demographics as well as potential for confounding. These covariates 
were then analyzed for model inclusion using a stepwise technique described elsewhere [25], the 
results of which are summarized in Table 2. While there was a statistically significant difference 
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in race between the stratified groups, the populations were almost entirely homogenous (white), 
therefore decided that the variable would not help our predictions. The study protocol was 
approved by the the Institutional Review Board at the University of Kentucky. 
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Results 
Sample Overview 
The characteristics of the total sample and sample stratified by ADMAPP compliancy as well as 
missing compliancy information is presented in Table 1. Overall the sample was a fairly evenly 
split between male and female, with no statistical differences in age, reason for original 
diagnosis, or the CCI between the ADMAPP compliancy stratified populations. Significant 
differences were observed in marital status, race, income, and specific AATD variant of the 
participant. By comparing the stratified populations we found majority of the selected variables 
were statistically different (Table 6). In addition, a choropleth map showing the number of 
participants per state is displayed in Figure 1, showing the geographical diversity of the 
population.  
 
Disease Knowledge and Treatment 
Initial analysis showed statistical differences between the stratified populations in all three of the 
disease knowledge and treatment outcome variables (Table 4). These variables included self-
reported comfort with knowledge of the disease, whether or not they had ever read any part of 
the BFRG, and if they were currently using any kind of augmentation therapy. Adjustment for 
possible cofounders using logistic regression (Table 5) revealed individuals compliant with 
ADMAPP were more likely to feel comfortable about their knowledge of the disease 
(ORadj=4.95, 95% CI: 3.24-7.57), have read any part of the BFRG (ORadj=6.44, 95% CI: 5.45-
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7.62), and twice as likely to be currently using augmentation therapy (ORadj=2.08, 95% CI: 1.53-
2.82). 
 
Exacerbating and Prophylactic Factors 
Initial analysis showed statistically significant differences for almost all of the exacerbating and 
preventive factors (Table 4). Prior to adjustment, significant increases in odds were observed in 
drinking status as well as all vaccination rates, while showing a decreased odds of smoking 
(Table 5). After adjusting for possible confounding, the increase in drinking status and 
pneumonia vaccination rates were no longer statistically significant. ADMAPP adherence was 
found to have a statistically significant, but marginal effect, on vaccination rates for flu in the last 
year (ORadj=1.34, 95% CI: 1.08-1.68), Hepatitis A (ORadj=1.41, 95% CI: 1.20-1.66), and 
Hepatitis B (ORadj=1.62, 95% CI: 1.37-1.91). Most notably, odds of ADMAPP adherent 
participants still being a smoker were greatly decreased (ORadj=0.47, CI: 0.31-0.70). 
 
Health and Health Perception 
Prior to logistic regression adjustment (Table 5), of all the health and health perception outcome 
variables examined, only exercise status (OR=2.21, 95% CI: 1.89-2.59), self-reported perception 
of weight (About Right vs Overweight, OR=1.17, 95% CI:  1.02-1.35), self-reported perception 
of physical health (Pretty fit/Getting fit/Very fit vs. Out of Shape, OR=1.68, 95% CI: 1.47-1.93), 
self-reported perception of overall health (Excellent/Good vs Fair/Poor, OR=1.32, 95% CI: 1.15-
1.51), if participant saw a physician other than the ones listed (OR=1.29, 95% CI:1.12-1.47), and 
if a participant had any unscheduled physician visits (OR=1.16, 95% CI: 1.01-1.33) were 
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statistically significant. After adjustment, only exercise status (ORadj=2.07, 95% CI: 1.74-2.47), 
self-reported perception of physical health (ORadj=1.66, 95% CI: 1.43-1.94) if participant saw a 
physician other than the ones listed (ORadj=1.28, 95% CI:1.10-1.50), and if a participant had any 
unscheduled physician visits (ORadj=1.27, 95% CI: 1.08-1.48).  
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Discussion 
Missing Completely at Random Assumption 
Missing information was a significant problem in this study, with 25.72% of subjects available in 
the dataset having no information on ADMAPP adherence. While there is no consensus on the 
appropriate way to determine when missing data is considered missing completely at random 
(MCAR), it is an important consideration for this study. To address this issue, demographic and 
outcome variables were arbitrarily selected and compared between the population with 
ADMAPP adherence information and the missing population. 
 
After analysis, 11 of the 16 demographic characteristics and outcomes examined (Table 6) were 
found to be significantly different between the two populations. While these findings suggest the 
data is not MCAR there is a large number of missing information within the missing population. 
Of the 11 variables found to significantly different, 9 had a majority of missing observations. 
Taken together, these findings make it difficult to conclude the nature of the missing data.  
 
ADMAPP Adherent Participants are More Informed About AATD 
Self-reported comfort with knowledge on ATTD, as well as utilization of the BFRG were 
associated with the largest odds ratio increase of all the outcome variables examined. The 
information contained within the BFRG is extensive, covering a multitude of topics that are 
related to ATTD and the observed increase in utilization is substantial. The guide itself is the 
largest part of the ADMAPP program so these results suggest that individuals are reading the 
guide and are retaining information from it, which may translate into prophylactic behavioral 
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changes. These results must be interpreted cautiously though, as this is not a validated measure 
of change in participant knowledge and is relative to the person answering the question. It does 
not measure whether or not the knowledge is correct, merely whether or not they feel 
comfortable with their knowledge. 
 
Physician and Emergency Medical Service Utilization 
The interpretation of the overall physician and emergency medical services utilization is difficult 
for this data set and must be done cautiously. For the purposes of this analysis, health provider 
visits (primary care, lung or liver specialist, other MD) were considered preventive measures. 
This was done because the BRFG suggests annual or biannual visits to a primary care physician 
and other physicians visits as necessary, which is the rational for doing logistic regression with 
physician visits being categorized as a binary outcome (did or did not use). It could be 
understandably argued that these same outcomes could be a negative indication.  
 
Interestingly, in unadjusted analysis (Table 4), the average number of primary care visits was 
higher in the non-adherent group, although the increase is not clinically significant. Once the 
primary care visits were re-categorized as a binary variable, this difference was lost, leaving only 
a slight increase in odds of “other” physician utilization. Considering the large number of 
physician specialties completely unrelated to ATTD, it is impossible to confidently draw any 
conclusions on the implications of these findings. 
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Prophylactic Measures Associated with ADMAPP Adherence  
Since there is currently no cure for AATD, much of the treatment information for individuals 
with the condition focuses on prophylactic measures that can be taken to decrease the burden of 
disease on the individual. Generally, these measures are focused on preventing xenobiotic and 
infectious insult to the lungs or liver, and healthy lifestyle choices. Ultimately, the aim is to 
avoid a pro-inflammatory environment. 
 
Smoking is a major cause of inflammation in the lungs, increasing host damage due to AATD, 
and as such, is a major focus of the ADMAPP. This study found that ADMAPP adherent 
individuals were far less likely to be active smokers, which is clinically significant (Table 5). In 
addition, these individuals were more likely to be vaccinated for the flu in the past year, hepatitis 
A, hepatitis B, which can be more serious in individuals with AATD, and recommended 
vaccinations in the BFRG. Pneumonia vaccination rates were also significantly increased in the 
adherent population prior to adjustment, but were not statistically significant in the logistic 
regression model. Taken together these results are encouraging and suggest that the ADMAPP 
adherent individuals are more likely to take an active effort in reducing the chances aggravating 
their condition.  
 
Perceived Health and Fitness 
A number of questions on the survey dealt with the subject’s perception of their general health 
and fitness as well as their exercise habits. The initial comparisons (Table 4) suggested several 
instances of distinction between the two populations. Adjustment for covariates showed 
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perceived fitness and exercise habits as being the only two statistically significant differences. 
Like the other results presented, these conclusions should also be carefully interpreted.  
 
For the perceived fitness question, the comparison was between individuals who answered “out 
of shape” and those who answered any of the other options (“getting fit”, “pretty fit”, “very fit”). 
These, like many of the other questions, have subjective answers that are relative to the observer, 
meaning one person’s definition of “pretty fit” could be another person’s definition of “out of 
shape.” This question may also be influenced by what can be referred to as “wishful thinking,” 
meaning reporting may be based on what makes the individual feel better as opposed to reality. 
 
While the ADMAPP adherent population was also found to be more likely to exercise, caution 
should also be used when correlating the two questions. The exercise observation was a 
combination of answers, similar to the perceived fitness question. Originally, study participants 
were given the option of choosing no exercise or four additional options that included various 
locations and regularity of exercise. These answers were combined so that any answer besides no 
exercise, was coded as a yes. For the purposes of this study, it was decided that the regularity of 
the exercise or location were not imperative to final interpretation, but the effort of exercise was.  
 
Even with these limitations, the conclusion that ADMAPP adherent individuals are more likely 
to exercise and have a positive image of their fitness remains fairly strong. It was not surprising 
to not see a corresponding change in BMI or perceived weight. Significant changes in weight 
would be the result of long term changes to multiple aspects of a person’s lifestyle. Considering 
the lack of temporality of this data, it is impossible to state how long people have been involved 
 25 
 
in the program and therefore the impact of the program on that aspect may just not be visible at 
the time of the survey.  
 
The lack of differences between the perceived health of the total populations was equally 
unsurprising. Health is an encompassing term and can mean many things to different people. 
Without the explicitly stating in the question was aspects of health the questionnaire was 
referring to (e.g., mental health, physical health, conditions unrelated to AATD), a statistically 
significant difference would be difficult to interpret in the proper context.  
 
Limitations 
There are several important limitations of this study that should be considered along with the 
results. First, all of the information, including the medical history, was collected via a self-report 
questionnaire which brings into question the validity of the information provided. The self-report 
nature of the study brings in recall bias (how accurate a person was able to remember 
information), reporting bias (selective revealing or suppressing of information by the 
participant), as well as a degree of social desirability bias (participants providing answers that 
they think are correct or desired). The data also lacked a longitudinal component, meaning the 
associations presented cannot be used to infer causality. In addition to this, there was also a 
significant proportion of missing data and nonsensical entries, which are discussed in the 
methodology section. The proportion of missing entries for the question concerning ADMAPP 
compliance was 25.72%, meaning our results may under- or overestimate the true results. 
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Conclusions 
While missing observations continue to be a limitation of this study, the large sample size and 
observations about the missing population alleviate some of the concerns about the missing 
information. As this study indicates an association between ADMAPP adherence several 
preventive outcomes, future studies need to be conducted using longitudinal data on this 
population to determine if this relationship is causal. Ultimately, The results of this study display 
the positive impact the ADMAPP can have on individuals with AATD. Individuals who self-
reported their percent adherence to the program as being nonzero were more likely to be 
informed about their condition and taking preventive measures, such as smoking cessation, 
getting vaccinated for conditions that could magnify the effects of AATD, and increases in self-
reported exercise. 
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Additional Tables 
Table 2. Covariates determined to be significant for each outcome 
 Age Sex Income CCI 
Disease Knowledge and Treatment     
Comfort with disease knowledge (Comfortable vs not comfortable)   Y Y 
Have read any part of BFRG (Yes vs No)   Y Y 
Use augmentation therapy (Yes vs No) Y  Y  
     
Exacerbating and Prophylactic Factors     
Still smoking (Yes vs No) Y  Y  
Drinker (Yes vs No)  Y Y Y 
Vaccinations     
     Pneumonia in last 6 years (Yes vs No) Y  Y  
     Flu vaccine in last year (Yes vs No) Y  Y  
     Hepatitis A (Yes vs No) Y Y Y Y 
     Hepatitis B (Yes vs No) Y Y Y  
     
Health and Health Perception     
Exercise (Yes vs No) Y  Y Y 
BMI     
     (Normal vs Overweight/Obese) Y Y Y Y 
     (Normal vs Underweight)   Y  
Perceived weight     
     (About Right vs Underweight) Y  Y Y 
     (About Right vs Overweight) Y Y Y Y 
Perceived fitness (Pretty fit/Getting fit/Very fit vs Out of Shape) Y Y Y Y 
Perceived health (Good/Excellent vs Poor/Fair) Y  Y Y 
Health care provider visits     
     Primary care (> 1 visit vs 0 visits) Y Y Y Y 
     Lung specialist (> 1 visit vs 0 visits) Y Y   
     Liver specialist (> 1 visit vs 0 visits) Y   Y 
     Other MD (> 1 visit vs 0 visits) Y Y Y Y 
Emergency services utilization over past year     
     Hospital admittance (Yes vs No) Y  Y Y 
     ICU admittance (Yes vs No) Y  Y Y 
     ER (Yes vs No) Y  Y Y 
     Unscheduled MD visit (Yes vs No) Y  Y Y 
Percent significant 83.3% 37.5% 91.7% 70.8% 
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Table 3. Descriptive characteristics and statistics of the study population  
 Total Population 
n=4,747 
# (%) 
Non-Adherent  
ADMAPP Users 
n=1,921 
# (%) 
Adherent 
ADMAPP Users 
n=1.605 
# (%) 
 
 
 
P-Values 
 
Missing 
n=1,221 
# (%) 
Sex    0.059  
     Male 2397 (50.50) 1,026 (53.41) 806 (50.22)  565 (46.27) 
     Female 2135 (44.98) 873 (45.45) 780 (48.60)  482 (39.48) 
     Missing 215 (4.53) 22 (1.15) 19 (1.18)  174 (14.25) 
Age (Mean + SD) 56.67 + 11.76 56.34 + 12.19 56.96 + 11.22 0.117 56.82 + 11.77 
Marital status    0.004  
     Married 2,787 (58.71) 1,141 (59.40) 1,042 (64.92)  604 (49.47) 
     Single 1,640 (34.55) 715 (37.22) 531 (33.08)  394 (32.27) 
     Missing 320 (6.74) 65 (3.38) 32 (1.99)  223 (18.26) 
Race    <0.001  
     White 4,399 (92.67) 1,825 (95.00) 1,563 (97.38)  1,011 (82.80) 
     Non-White 107 (2.25) 61 (3.18) 24 (1.50)  22 (1.80) 
     Missing 241 (5.08) 35 (1.82) 18 (1.12)  188 (15.40) 
Income    <0.001  
     <$20,000 1,150 (33.55) 564 (35.97) 371 (28.06)  215 (39.96) 
     $20,000-$40,000 910 (26.55) 414 (26.40) 361 (27.31)  135 (25.09) 
     $40,000-$$60,000 572 (16.69) 267 (17.03) 234 (17.70)  71 (13.20) 
     $60,000-$80,000 341 (9.95) 147 (9.38) 147 (11.12)  47 (8.74) 
     $80,000-$100,000 191 (5.57) 75 (4.78) 84 (6.35)  32 (5.95) 
     >$100,000 264 (7.70) 101 (6.44) 125 (9.46)  38 (7.06) 
     Missing 1,319 353 283  683 
AATD variant    <0.001  
     PI*ZZ 2,507 (52.81) 1,036 (53.93) 1,022 (63.68)  449 (36.77) 
     PI*MZ 522 (11.00) 196 (10.20) 140 (8.72)  186 (15.23) 
     PI*SZ 323 (6.80) 110 (5.73) 94 (5.86)  119 (9.75) 
     PI*ZNull 33 (0.70) 13 (0.68) 13 (0.81)  7 (0.57) 
     PI*NullNull 14 (0.29) 7 (0.36) 5 (0.31)  2 (0.16) 
     Other 162 (3.41) 54 (2.81) 55 (3.43)  53 (4.34) 
     Unknown 769 (16.20) 397 (20.67) 227 (14.14)  145 (11.88) 
     Missing 417 (8.78) 108 (5.62) 49 (3.05)  260 (21.29) 
Charlson Comorbidity Index (Mean + SD) 0.77 + 1.28 0.78 + 1.29 0.76 + 1.27 0.760 0.75 + 1.27 
     0 3004 (63.28) 1,200 (62.47) 1,017 (63.36) 0.927 787 (64.46) 
     1 725 (15.27) 308 (16.03) 240 (14.95)  177 (14.50) 
     2 567 (11.94) 231 (12.02) 196 (12.21)  140 (11.47) 
     3 218 (4.59) 84 (4.37) 75 (4.67)  59 (4.83) 
     4 113 (2.38) 48 (2.50) 36 (2.24)  29 (2.38) 
     5 53 (1.12) 20 (1.04) 20 (1.25)  13 (1.06) 
     >6 67 (1.41) 30 (1.56) 21 (1.31)  16 (1.31) 
Diagnosis prompt      
     Early onset lung disease    0.438  
          Yes 1,083 (22.81) 497 (25.87) 435 (27.10)  151 (12.37) 
          No 3,496 (73.65) 1,409 (73.35) 1,162 (72.40)  925 (75.76) 
          Missing 168 (3.54) 15 (0.78) 8 (0.50)  145 (11.88) 
     Emphysema    0.842  
          Yes 1,127 (23.74) 471 (24.52) 390 (24.30)  266 (21.79) 
          No 3,452 (72.72) 1,435 (74.70) 1,207 (75.20)  810 (66.34) 
          Missing 168 (3.54) 15 (0.078) 8 (0.50)  145 (11.88) 
     Uncontrolled asthma    0.205  
          Yes 593 (12.49) 235 (12.23) 220 (13.71)  138 (11.30) 
          No 3,986 (83.97) 1,671 (86.99) 1,377 (85.79)  938 (76.82) 
          Missing 168 (3.54) 15 (0.78) 8 (0.50)  145 (11.88) 
     Screening because relative has    0.730  
          Yes 666 (14.03) 286 (14.89) 233 (14.52)  147 (12.04) 
          No 3,913 (82.43) 1,620 (84.33) 1,364 (84.98)  929 (76.09) 
          Missing 168 (3.54) 15 (0.78) 8 (0.50)  145 (11.88) 
     Chronic bronchitis    0.080  
          Yes 672 (14.16) 272 (14.16) 262 (16.32)  138 (11.30) 
          No 3,907 (82.30) 1,634 (85.06) 1,335 (83.18)  938 (76.82) 
          Missing 168 (3.54) 15 (0.78) 8 (0.50)  145 (11.88) 
     Bronchiectasis    0.087  
          Yes 101 (2.13) 34 (1.77) 42 (2.62)  25 (2.05) 
          No 4,477 (94.31) 1,872 (97.45) 1,555 (96.88)  1,050 (86.00) 
          Missing 169 (3.56) 15 (0.78) 8 (0.50)  146 (11.96) 
     COPD    0.496  
          Yes 1,145 (24.12) 447 (23.27) 359 (22.37)  339 (27.76) 
          No 3,434 (72.34) 1,459 (75.95) 1,238 (77.13)  737 (60.36) 
          Missing 168 (3.54) 15 (0.78) 8 (0.50)  145 (11.88) 
     Cirrhosis    0.829  
          Yes 40 (0.84) 12 (0.62) 11 (0.69)  17 (1.39) 
          No 4,538 (95.60) 1,894 (98.59) 1,586 (98.82)  1,058 (86.65) 
          Missing 169 (3.56) 15 (0.78) 8 (0.50)  146 (11.96) 
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Table 4. Descriptive characteristics and statistics for outcome variables of interest 
 Total 
Population 
n=4,747 
# (%) 
Non-Adherent 
ADMAPP Users 
n=1,921 
# (%) 
Adherent 
ADMAPP Users 
n=1.605 
# (%) 
 
 
 
P-Values 
 
Missing 
n=1,221 
# (%) 
Disease Knowledge/Treatment      
Comfort with disease knowledge    <0.001  
     Not comfortable 268 (5.65) 147 (7.65) 36 (2.24)  85 (6.96) 
     Somewhat comfortable 2,109 (44.43) 960 (49.97) 574 (35.76)  575 (47.09) 
     Comfortable 2,114 (44.53) 782 (40.71) 974 (60.69)  358 (29.32) 
     Missing 256 (5.39) 32 (1.67) 21 (1.31)  203 (16.63) 
Read any part of BFRG    <0.001  
     Yes 1,886 (39.73) 518 (26.97) 1,126 (70.16)  242 (19.82) 
     No 2,180 (45.92) 1,361 (70.85) 461 (28.72)  358 (29.32) 
     Missing 681 (14.35) 42 (2.19) 18 (1.12)  621 (50.86) 
Use augmentation therapy    <0.001  
     Yes 3,750 (79.00) 1,679 (87.40) 1,500 (93.46)  571 (46.76) 
     No 383 (8.07) 190 (9.89) 83 (5.17)  110 (9.01) 
     Missing 614 (12.93) 52 (2.71) 22 (1.37)  540 (44.23) 
      
Exacerbating and Preventive Factors      
Smoking status    0.831  
     Never smoked 1,022 (21.53) 463 (24.10) 398 (24.80)  161 (13.19) 
     Have smoked 3,095 (65.20) 1,415 (73.66) 1,196 (74.52)  484 (39.64) 
     Missing 630 (13.27) 43 (2.24) 11 (0.69)  576 (47.17) 
          Still smoking    <0.001  
               Yes 185 (5.98) 107 (5.98) 38 (3.18)  40 (8.26) 
               No 2,893 (93.47) 1,295 (91.52) 1,157 (96.74)  441 (91.12) 
               Missing 17 (0.55) 13 (0.92) 1 (0.08)  3 (0.62) 
Drinking habits    0.001  
     Don’t drink 2,340 (49.29) 1,093 (56.90) 842 (52.46)  405 (33.17) 
     Drink 1,716 (36.15) 757 (39.41) 727 (45.30)  232 (19.00) 
     Missing 691 (14.56) 71 (3.70) 36 (2.24)  584 (47.83) 
          Weekly Drinks (Mean + SD) 5.52 + 6.69 5.79 + 7.07 5.50 + 6.55 0.416 4.72 + 5.77 
Vaccinations      
     Pneumonia in last 6 years    0.017  
          Yes 3,488 (73.48) 1,586 (82.56) 1,391 (86.67)  511 (41.85) 
          No 529 (11.14) 255 (13.27) 174 (10.84)  100 (8.19) 
          Missing 730 (15.38) 80 (4.16) 40 (2.49)  610 (49.96) 
     Flu vaccine in last year    <0.001  
          Yes 3,522 (74.19) 1,592 (82.87) 1,409 (87.79)  521 (42.67) 
          No 574 (12.09) 285 (14.84) 176 (10.97)  113 (9.25) 
          Missing 651 (13.71) 44 (2.29) 20 (1.25)  587 (48.08) 
     Hepatitis A    <0.001  
          Yes 1,578 (33.24) 677 (35.24) 733 (45.67)  168 (13.76) 
          No 1,835 (38.66) 864 (44.98) 620 (38.63)  351 (28.75) 
          Missing 1,334 (28.10) 380 (19.78) 252 (15.70)  702 (57.49) 
     Hepatitis B    <0.001  
          Yes 2,225 (46.87) 957 (49.82) 1,046 (65.17)  222 (18.18) 
          No 1,430 (30.12) 681 (35.45) 427 (26.60)  322 (26.37) 
          Missing 1,092 (23.00) 283 (14.73) 132 (8.22)  677 (55.45) 
      
General Health Information      
Body mass index (BMI)    0.274  
     Underweight 212 (4.47) 91 (4.74) 76 (4.74)  45 (3.69) 
     Normal 1,553 (32.72) 655 (34.10) 580 (36.14)  318 (26.04) 
     Overweight 1,249 (26.31) 515 (26.81) 439 (27.35)  295 (24.16) 
     Obese 1,304 (21.78) 443 (23.06) 328 (20.44)  263 (21.54) 
     Missing 699 (14.73) 217 (11.30) 182 (11.34)  300 (24.57) 
Perceived weight    0.084  
     Underweight 482 (10.15) 225 (11.71) 184 (11.46)  73 (5.98) 
     About right 1,605 (33.81) 716 (37.27) 665 (41.43)  224 (18.35) 
     Overweight 2,009 (42.32) 930 (48.41) 736 (45.86)  343 (28.09) 
     Missing 651 (13.71) 50 (2.60) 20 (1.25)  581 (47.58) 
Perceived fitness    <0.001  
     Out of shape 1,967 (41.44) 982 (51.12) 632 (39.38)  353 (28.91) 
     Pretty fit 1,205 (25.38) 502 (26.13) 531 (33.08)  172 (14.09) 
     Getting fit 781 (16.45) 323 (16.81) 351 (21.87)  107 (8.76) 
     Very fit 115 (2.42) 45 (2.34) 61 (3.80)  9 (0.74) 
     Missing 679 (14.30) 69 (3.59) 30 (1.87)  580 (47.50) 
Perceived Health    <0.001  
     Poor 781 (16.45) 378 (19.68) 273 (17.01)  130 (10.65) 
     Fair 1,745 (36.76) 826 (43.00) 646 (40.25)  273 (22.36) 
     Good 1,407 (29.64) 601 (31.29) 589 (36.70)  217 (17.77) 
     Excellent 152 (3.20) 58 (3.02) 74 (4.61)  20 (1.64) 
     Missing 662 (13.95) 58 (3.02) 23 (1.43)  581 (47.58) 
Exercise Habits    <0.001  
     Exercise 2,720 (57.30) 1,103 (57.42) 1,192 (74.27)  425 (34.81) 
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     Don’t exercise 1,206 (25.41) 661 (34.41) 323 (20.12)  222 (18.18) 
     Missing 821 (17.30) 157 (8.17) 90 (5.61)  574 (47.01) 
Health Provider Visits 
(Mean + SD), past year 
     
     Primary care 3.30 + 2.00 3.32 + 2.05 3.13 + 1.96 0.006 3.53 + 1.94 
     Lung specialist 3.00 + 1.75 3.01 + 1.74 2.94 + 1.76 0.280 3.04 + 1.76 
     Liver specialist 0.19 + 0.79 0.17 + 0.71 0.20 + 0.81 0.240 0.24 + 0.88 
     Other MD 1.76 + 2.08 1.66 + 2.08 1.81 + 2.06 0.048 1.87 + 2.11 
Emergency Service Visits 
(Mean + SD), past year 
     
     Hospital admittance 0.70 + 1.30 0.72 + 1.35 0.63 + 1.21 0.046 0.76 + 1.34 
     Intensive Care Unit admittance 0.13 + 0.50 0.13 + 0.53 0.12 + 0.45 0.549 0.13 + 0.50 
     Emergency room 0.63 + 1.27 0.67 + 1.32 0.59 + 1.19 0.061 0.65 + 1.31 
     Unscheduled MD visit 0.98 + 1.64 0.91 + 1.58 1.03 + 1.66 0.032 1.01 + 1.74 
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Table 5. Comparison of outcome variables between ADMAPP adherent to non-adherent populations 
using logistic regression  
 Crude Odds ratio 
(95% CI) 
Adjusted Odds Ratio  
(95% CI) 
Disease Knowledge and Treatment   
Comfort with disease knowledge (Comfortable vs not comfortable) 5.09 (3.49-7.41) 4.95 (3.24-7.57) 
Have read any part of BFRG (Yes vs No) 6.42 (5.53-7.44) 6.44 (5.45-7.62) 
Use augmentation therapy (Yes vs No) 2.05 (1.57-2.67) 2.08 (1.53-2.82) 
   
Exacerbating and Prophylactic Factors   
Still smoking (Yes vs No) 0.40 (0.27-0.58) 0.47 (0.31-0.70) 
Drinker (Yes vs No) 1.25 (1.09-1.43) 1.12 (0.96-1.31) 
Vaccinations   
     Pneumonia in last 6 years (Yes vs No) 1.29 (1.05-1.58) 1.14 (0.90-1.44) 
     Flu vaccine in last year (Yes vs No) 1.43 (1.17-1.75) 1.34 (1.08-1.68) 
     Hepatitis A (Yes vs No) 1.51 (1.30-1.74) 1.41 (1.20-1.66) 
     Hepatitis B (Yes vs No) 1.74 (1.50-2.02) 1.62 (1.37-1.91) 
   
Health and Health Perception   
Exercise (Yes vs No) 2.21 (1.89-2.59) 2.07 (1.74-2.47) 
BMI   
     (Normal vs Overweight/Obese) 1.11 (0.96-1.28) 1.04 (0.88-1.23) 
     (Normal vs Underweight) 1.06 (0.77-1.47) 0.99 (0.68-1.44) 
Perceived weight   
     (About Right vs Underweight) 1.14 (0.91-1.42) 1.03 (0.80-1.33) 
     (About Right vs Overweight) 1.17 (1.02-1.35) 1.12 (0.95-1.31) 
Perceived fitness (Pretty fit/Getting fit/Very fit vs Out of Shape) 1.68 (1.47-1.93) 1.66 (1.43-1.94) 
Perceived health (Good/Excellent vs Poor/Fair) 1.32 (1.15-1.51) 1.16 (0.98-1.36) 
Health care provider visits   
     Primary care (> 1 visit vs 0 visits) 1.15 (0.91-1.46) 1.22 (0.94-1.60) 
     Lung specialist (> 1 visit vs 0 visits) 1.01 (0.75-1.36) 1.07 (0.77-1.48) 
     Liver specialist (> 1 visit vs 0 visits) 1.13 (0.88-1.45) 1.13 (0.85-1.50) 
     Other MD (> 1 visit vs 0 visits) 1.29 (1.12-1.47) 1.28 (1.10-1.50) 
Emergency services utilization over past year   
     Hospital admittance (Yes vs No) 0.89 (0.78-1.03) 0.94 (0.80-1.11) 
     ICU admittance (Yes vs No) 1.06 (0.84-1.33) 1.15 (0.89-1.50) 
     ER (Yes vs No) 0.89 (0.77-1.03) 1.00 (0.84-1.18) 
     Unscheduled MD visit (Yes vs No) 1.16 (1.01-1.33) 1.27 (1.08-1.48) 
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Table 6. Results of testing for for missing ADMAPP adherence data 
 Have Information on 
ADMAPP Adherence 
n=3,526 
# (%) 
Missing Information on 
ADMAPP Adherence 
n=1,221 
# (%) 
 
 
 
P-value 
Sex   0.428 
     Male 1,832 (51.96) 565 (46.27)  
     Female 1,653 (46.88) 482 (39.48)  
     Missing 41 (1.16) 174 (14.25)  
Marital status   0.705 
     Married 2,183 (61.91) 604 (49.47)  
     Single 1,246 (35.34) 394 (32.27)  
     Missing 97 (2.75) 253 (20.72)  
Race   0.550 
     White 3,388 (96.09) 1,011 (82.80)  
     Non-White 85 (2.41) 22 (1.80)  
     Missing 53 (1.50) 188 (15.40)  
Income   0.013 
     <$20,000 935 (26.52) 215 (17.61)  
     $20,000-$40,000 775 (21.98) 135 (11.06)  
     $40,000-$$60,000 501 (14.21) 71 (5.81)  
     $60,000-$80,000 294 (8.34) 47 (3.85)  
     $80,000-$100,000 159 (4.51) 32 (2.62)  
     >$100,000 226 (6.41) 38 (3.11)  
     Missing 636 (18.04) 683 (55.94)  
Comfort with disease knowledge   <0.001 
     Not comfortable 183 (5.19) 85 (6.96)  
     Somewhat comfortable 1,534 (43.51) 575 (47.09)  
     Comfortable 1,756 (49.80) 358 (29.32)  
     Missing 53 (1.50) 203 (16.63)  
Read any part of BFRG   0.001 
     Yes 1,644 (46.63) 242 (19.82)  
     No 1,822 (51.67) 358 (29.32)  
     Missing 60 (1.70) 621 (50.86)  
Pneumonia vaccine in last 6 years   0.011 
     Yes 2,977 (84.43) 511 (41.85)  
     No 429 (12.17) 100 (8.19)  
     Missing 120 (3.40) 610 (49.96)  
Flu vaccine in last year   0.003 
     Yes 3,001 (85.11) 521 (42.67)  
     No 461 (13.07) 113 (9.25)  
     Missing 64 (1.82) 587 (48.08)  
 Hepatitis A vaccine   <0.001 
     Yes 1,410 (39.99) 168 (13.76)  
     No 1,484 (42.09) 351 (28.75)  
     Missing 632 (17.92) 702 (57.49)  
Hepatitis B vaccine   <0.001 
     Yes 2,003 (56.81) 222 (18.18)  
     No 1,108 (31.42) 322 (26.37)  
     Missing 415 (11.77) 677 (55.45)  
Body mass index (BMI)   0.022 
     Underweight 167 (4.74) 45 (3.69)  
     Normal 1,235 (35.03) 318 (26.04)  
     Overweight 954 (27.06) 295 (24.16)  
     Obese 771 (21.87) 263 (21.54)  
     Missing 399 (11.32) 300 (24.57)  
Perceived weight   0.036 
     Underweight 409 (11.60) 73 (5.98)  
     About right 1,381 (39.17) 224 (18.35)  
     Overweight 1,666 (47.25) 343 (28.09)  
     Missing 70 (1.99) 581 (47.58)  
Perceived fitness   <0.001 
     Out of shape 1,614 (45.77) 353 (28.91)  
     Pretty fit 1,033 (29.30) 172 (14.09)  
     Getting fit 674 (19.12) 107 (8.76)  
     Very fit 106 (3.01) 9 (0.74)  
     Missing 99 (2.81) 580 (47.50)  
Perceived Health   0.716 
     Poor 651 (18.46) 130 (10.65)  
     Fair 1,472 (41.75) 273 (22.36)  
     Good 1,190 (33.75) 217 (17.77)  
     Excellent 132 (3.74) 20 (1.64)  
     Missing 81 (2.30) 581 (47.58)  
Exercise Habits   0.030 
     Exercise 2,295 (65.09) 425 (34.81)  
     Don’t exercise 984 (27.91) 222 (18.18)  
     Missing 247 (7.01) 574 (47.01)  
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Additional Figures 
 
 
Figure 2. Choropleth map showing state of residence of study participants
 35 
 
References 
 
 1.	 Laurell,	C.B.	and	S.	Eriksson,	The	electrophoretic	alpha1-globulin	pattern	of	
serum	in	alpha1-antitrypsin	deficiency.	1963.	COPD,	2013.	10	Suppl	1:	p.	3-8.	2.	 Needham,	M.	and	R.A.	Stockley,	Alpha	1-antitrypsin	deficiency.	3:	Clinical	
manifestations	and	natural	history.	Thorax,	2004.	59(5):	p.	441-5.	3.	 Kohnlein,	T.	and	T.	Welte,	Alpha-1	antitrypsin	deficiency:	pathogenesis,	clinical	
presentation,	diagnosis,	and	treatment.	Am	J	Med,	2008.	121(1):	p.	3-9.	4.	 Crystal,	R.G.,	Alpha	1-antitrypsin	deficiency,	emphysema,	and	liver	disease.	
Genetic	basis	and	strategies	for	therapy.	J	Clin	Invest,	1990.	85(5):	p.	1343-52.	5.	 Barker,	A.F.,	et	al.,	Replacement	therapy	for	hereditary	alpha1-antitrypsin	
deficiency.	A	program	for	long-term	administration.	Chest,	1994.	105(5):	p.	1406-10.	6.	 Abboud,	R.T.,	G.T.	Ford,	and	K.R.	Chapman,	Emphysema	in	alpha1-antitrypsin	
deficiency:	does	replacement	therapy	affect	outcome?	Treat	Respir	Med,	2005.	
4(1):	p.	1-8.	7.	 Petrache,	I.,	J.	Hajjar,	and	M.	Campos,	Safety	and	efficacy	of	alpha-1-antitrypsin	
augmentation	therapy	in	the	treatment	of	patients	with	alpha-1-antitrypsin	
deficiency.	Biologics,	2009.	3:	p.	193-204.	8.	 AlphaNet.	ADMAP:	Alpha-1	Disease	Management	and	Prevention	Program.	Available	from:	http://www.alphanet.org/admapp-alpha-1-disease-
management-and-prevention-program/.	9.	 Stoller,	J.K.	and	L.S.	Aboussouan,	A	review	of	alpha1-antitrypsin	deficiency.	Am	J	Respir	Crit	Care	Med,	2012.	185(3):	p.	246-59.	10.	 DeMeo,	D.L.	and	E.K.	Silverman,	Alpha1-antitrypsin	deficiency.	2:	genetic	
aspects	of	alpha(1)-antitrypsin	deficiency:	phenotypes	and	genetic	modifiers	of	
emphysema	risk.	Thorax,	2004.	59(3):	p.	259-64.	11.	 Fregonese,	L.,	et	al.,	Alpha-1	antitrypsin	Null	mutations	and	severity	of	
emphysema.	Respir	Med,	2008.	102(6):	p.	876-84.	12.	 Silverman,	E.K.,	et	al.,	Family	study	of	alpha	1-antitrypsin	deficiency:	effects	of	
cigarette	smoking,	measured	genotype,	and	their	interaction	on	pulmonary	
function	and	biochemical	traits.	Genet	Epidemiol,	1992.	9(5):	p.	317-31.	
 36 
 
13.	 Blanco,	I.,	et	al.,	Estimated	numbers	and	prevalence	of	PI*S	and	PI*Z	alleles	of	
alpha1-antitrypsin	deficiency	in	European	countries.	Eur	Respir	J,	2006.	27(1):	p.	77-84.	14.	 de	Serres,	F.J.,	Worldwide	racial	and	ethnic	distribution	of	alpha1-antitrypsin	
deficiency:	summary	of	an	analysis	of	published	genetic	epidemiologic	surveys.	Chest,	2002.	122(5):	p.	1818-29.	15.	 Luisetti,	M.	and	N.	Seersholm,	Alpha1-antitrypsin	deficiency.	1:	epidemiology	
of	alpha1-antitrypsin	deficiency.	Thorax,	2004.	59(2):	p.	164-9.	16.	 Stoller,	J.K.,	F.L.	Lacbawan,	and	L.S.	Aboussouan,	Alpha-1	Antitrypsin	
Deficiency,	in	GeneReviews(R),	R.A.	Pagon,	et	al.,	Editors.	1993:	Seattle	(WA).	17.	 de	Serres,	F.J.,	Alpha-1	antitrypsin	deficiency	is	not	a	rare	disease	but	a	disease	
that	is	rarely	diagnosed.	Environ	Health	Perspect,	2003.	111(16):	p.	1851-4.	18.	 Stoller,	J.K.	and	L.S.	Aboussouan,	Alpha1-antitrypsin	deficiency.	Lancet,	2005.	
365(9478):	p.	2225-36.	19.	 Fairbanks,	K.D.	and	A.S.	Tavill,	Liver	disease	in	alpha	1-antitrypsin	deficiency:	
a	review.	Am	J	Gastroenterol,	2008.	103(8):	p.	2136-41;	quiz	2142.	20.	 Kohnlein,	T.	and	T.	Welte,	Alpha-1	antitrypsin	deficiency:	pathogenesis,	clinical	
presentation,	diagnosis,	and	treatment.	Am	J	Med,	2008.	121(1):	p.	3-9.	21.	 Fregonese,	L.	and	J.	Stolk,	Hereditary	alpha-1-antitrypsin	deficiency	and	its	
clinical	consequences.	Orphanet	J	Rare	Dis,	2008.	3:	p.	16.	22.	 Campos,	M.A.,	et	al.,	Effects	of	a	disease	management	program	in	individuals	
with	alpha-1	antitrypsin	deficiency.	COPD,	2009.	6(1):	p.	31-40.	23.	 Prevention,	C.f.D.C.a.	About	Adult	BMI.	May	15,	2015;	Available	from:	
http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/.	24.	 Charlson,	M.E.,	et	al.,	A	new	method	of	classifying	prognostic	comorbidity	in	
longitudinal	studies:	development	and	validation.	J	Chronic	Dis,	1987.	40(5):	p.	373-83.	25.	 Bursac,	Z.,	et	al.,	Purposeful	selection	of	variables	in	logistic	regression.	Source	Code	Biol	Med,	2008.	3:	p.	17.	
 
